+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 12Months - 30Years
All Genders
ID04901702

Phase III Study of Onivyde Combined with Talazoparib or Temozolomide for Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors Including Ewing Sarcoma

Led by St. Jude Children's Research Hospital · Updated on 2026-05-19

90

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate two treatment combinations in children, adolescents, and young adults with solid tumors or Ewing sarcoma that have returned or are resistant to previous treatments. The trial includes a phase I dose-finding portion and a phase II study focused on Ewing sarcoma, assessing the highest tolerable doses and comparing progression-free survival between the two treatment arms. The study is sponsored by St. Jude Childrens Research Hospital and involves patients aged 1 to 30 years with refractory or recurrent solid tumors or Ewing sarcoma. In phase I, participants are randomly assigned to one of two treatment arms. Arm A receives intravenous Onivyde on Days 1 and 8 plus oral talazoparib twice on Day 1 and daily on Days 2 to 6. Arm B receives intravenous Onivyde on Days 1 and 8 plus oral temozolomide daily on Days 1 to 5. After establishing the highest tolerable doses, expansion cohorts will enroll more patients to assess tumor response. Phase II will then randomize patients with recurrent or refractory Ewing sarcoma to receive the same two regimens. Participants will undergo tumor assessments at the start and after cycles 2, 4, 6, and every 4 cycles afterward. Pharmacokinetic testing occurs during the first cycle. Treatment may continue for up to 24 months unless disease progression or significant toxicities occur. Safety and tolerability are monitored throughout. The primary outcomes include determining recommended doses in phase I and progression-free survival in phase II. Secondary measures include safety, tumor response, and drug pharmacokinetics, with follow-up lasting up to five years after randomization in phase II.

CONDITIONS

Brief Title

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Research Team

S

Sara Federico, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here